Transgelin Promotes Glioblastoma Stem Cell Hypoxic Responses and Maintenance Through p53 Acetylation

Adv Sci (Weinh). 2024 Feb;11(7):e2305620. doi: 10.1002/advs.202305620. Epub 2023 Dec 12.

Abstract

Glioblastoma (GBM) is a lethal cancer characterized by hypervascularity and necrosis associated with hypoxia. Here, it is found that hypoxia preferentially induces the actin-binding protein, Transgelin (TAGLN), in GBM stem cells (GSCs). Mechanistically, TAGLN regulates HIF1α transcription and stabilizes HDAC2 to deacetylate p53 and maintain GSC self-renewal. To translate these findings into preclinical therapeutic paradigm, it is found that sodium valproate (VPA) is a specific inhibitor of TAGLN/HDAC2 function, with augmented efficacy when combined with natural borneol (NB) in vivo. Thus, TAGLN promotes cancer stem cell survival in hypoxia and informs a novel therapeutic paradigm.

Keywords: HDAC2; HIF1α Hypoxia; glioblastoma stem cells; natural borneol; sodium valproate; transgelin.

MeSH terms

  • Acetylation
  • Brain Neoplasms* / metabolism
  • Glioblastoma* / drug therapy
  • Glioblastoma* / metabolism
  • Humans
  • Hypoxia / metabolism
  • Microfilament Proteins / metabolism
  • Muscle Proteins*
  • Neoplastic Stem Cells / metabolism
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • transgelin
  • Tumor Suppressor Protein p53
  • Microfilament Proteins
  • Muscle Proteins